Impact of the 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene on primary nephrotic syndrome

Luo,Yuezhong; Wang,Chao; Tu,Haitao

doi:10.3892/mmr.2014.1903

Impact of the 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene on primary nephrotic syndrome

Authors:
- Yuezhong Luo
- Chao Wang
- Haitao Tu
View Affiliations

Affiliations: Division of Nephrology, First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou 510405, P.R. China
Published online on: January 17, 2014 https://doi.org/10.3892/mmr.2014.1903
Pages: 894-898

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate whether the four guanosines (4G)/five guanosines (5G) polymorphism in the gene coding for plasminogen activator inhibitor-1 (PAI-1) affects the clinical features of primary nephrotic syndrome (PNS). A cohort of 200 biopsy-diagnosed PNS patients was studied, with 40 healthy subjects as controls. The PAI-1 gene polymorphism was detected by polymerase chain reaction and DNA sequencing. Associations between the PAI-1 4G/5G polymorphism and clinical features and pathological types of PNS were analyzed. The results indicated that the PAI-1 genotype distribution is significantly different between patients with PNS and healthy controls, with significantly higher numbers of the 4G/4G genotype and lower numbers of the 5G5G genotype detected in PNS patients compared to controls (both P<0.05). The frequency of the 4G allele was also significantly higher in PNS patients compared to healthy controls (P<0.01). Among the different pathological types of PNS, IgA nephropathy (IgAN) and membranous nephropathy (MN) were associated with significantly increased frequencies of the 4G/4G and 4G/5G genotypes, as well as of the 4G allele. The increased 4G frequency was also detected in patients with minimal change disease (MCD). Significantly increased international normalized ratio (INR) and prolonged activated partial thromboplastin time (APTT) were observed in 4G/4G compared to 5G/5G PNS subjects. The response to steroids was not significantly different among the three genotypes. In conclusion, the 4G allele of the PAI-1 gene appears to be associated with PNS, especially in MN and IgAN patients. These findings suggest that specific targeting may be required for the treatment of PNS patients with the 4G/4G genotype.

View Figures

View References

1	Koenig W: Haemostatic risk factors for cardiovascular diseases. Eur Heart J. 19:C39–C43. 1998.
2	Bennett WM: Letter: renal vein thrombosis in nephrotic syndrome. Ann Intern Med. 83:577–578. 1975. View Article : Google Scholar : PubMed/NCBI
3	Wang A, Wang Y, Wang G, Zhou Z, Xun Z and Tan X: Mesangial IgA deposits indicate pathogenesis of antiglomerular basement membrane disease. Mol Med Rep. 5:1212–1214. 2012.PubMed/NCBI
4	Chugh KS, Malik N, Uberoi HS, Gupta VK, Aggarwal ML and Singhal PC: Renal vein thrombosis in nephrotic syndrome - a prospective study and review. Postgrad Med J. 57:566–570. 1981. View Article : Google Scholar : PubMed/NCBI
5	Zhu Y, Yin WL, Ba YF, Tian L, Gu ZQ, Zhang MS and Zhong CN: Transforming growth factor-1 promotes transcriptional activation of plasminogen activator inhibitor type 1 in carcinoma-associated fibroblasts. Mol Med Rep. 6:1001–1005. 2012.
6	Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S and Henney AM: The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem. 268:10739–10745. 1993.PubMed/NCBI
7	Burzotta F, Di Castelnuovo A, Amore C, D’Orazio A, Di Bitondo R and Donati MB: 4G/5G promoter PAI-1 gene polymorphism is associated with plasmatic PAI-1 activity in Italians: a model of gene-environment interaction. Thromb Haemostasis. 79:354–358. 1998.PubMed/NCBI
8	Nagano K, Ishida J, Unno M, Matsukura T and Fukamizu A: Apelin elevates blood pressure in ICR mice with L-NAME-induced endothelial dysfunction. Mol Med Rep. 7:1371–1375. 2013.PubMed/NCBI
9	Diamanti-Kandarakis E, Palioniko G, Alexandraki K, Bergiele A, Koutsouba T and Bartzis M: The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels. Eur J Endocrinol. 150:793–798. 2004. View Article : Google Scholar : PubMed/NCBI
10	Tsantes AE, Nikolopoulos GK, Bagos PG, Rapti E, Mantzios G, Kapsimali V and Travlou A: Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and venous thrombosis. A meta-analysis. Thromb Haemostasis. 97:907–913. 2007.PubMed/NCBI
11	Binder A, Endler G, Muller M, Mannhalter C and Zenz W: 4G4G genotype of the plasminogen activator inhibitor-1 promoter polymorphism associates with disseminated intravascular coagulation in children with systemic meningococcemia. J Thromb Haemost. 5:2049–2054. 2007. View Article : Google Scholar
12	Hoekstra T, Geleijnse JM, Schouten EG and Kluft C: Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk. Thromb Haemostasis. 91:861–872. 2004.PubMed/NCBI
13	Kanfer A: Coagulation factors in nephrotic syndrome. Am J Nephrol. 10:63–68. 1990. View Article : Google Scholar
14	Rabelink TJ, Zwaginga JJ, Koomans HA and Sixma JJ: Thrombosis and hemostasis in renal disease. Kidney Int. 46:287–296. 1994. View Article : Google Scholar : PubMed/NCBI
15	Deguchi F, Tomura S, Yoshiyama N and Takeuchi J: Intraglomerular deposition of coagulation-fibrinolysis factors and a platelet membrane antigen in various glomerular diseases. Nephron. 51:377–383. 1989. View Article : Google Scholar
16	Sraer JD, Kanfer A, Rondeau E and Lacave R: Glomerular hemostasis in normal and pathologic conditions. Adv Nephrol Necker Hosp. 17:27–55. 1988.PubMed/NCBI
17	Thomson C, Forbes CD, Prentice CR and Kennedy AC: Changes in blood coagulation and fibrinolysis in the nephrotic syndrome. Q J Med. 43:399–407. 1974.PubMed/NCBI
18	Yoshida Y, Shiiki H, Iwano M, Uyama H, Hamano K, Nishino T and Dohi K: Enhanced expression of plasminogen activator inhibitor 1 in patients with nephrotic syndrome. Nephron. 88:24–29. 2001. View Article : Google Scholar : PubMed/NCBI
19	Ma Z, Jhun B, Jung SY and Oh CK: Binding of upstream stimulatory factor 1 to the E-box regulates the 4G/5G polymorphism-dependent plasminogen activator inhibitor 1 expression in mast cells. J Allergy Clin Immun. 121:1006–1012. 2008. View Article : Google Scholar
20	White LA, Bruzdzinski C, Kutz SM, Gelehrter TD and Higgins PJ: Growth state-dependent binding of USF-1 to a proximal promoter E box element in the rat plasminogen activator inhibitor type 1 gene. Expe Cell Res. 260:127–135. 2000. View Article : Google Scholar : PubMed/NCBI
21	Qi L, Allen RR, Lu Q, Higgins CE, Garone R, Staiano-Coico L and Higgins PJ: PAI-1 transcriptional regulation during the G0→G1 transition in human epidermal keratinocytes. J Cell Biochem. 99:495–507. 2006.
22	Bendall AJ and Molloy PL: Base preferences for DNA binding by the bHLH-Zip protein USF: effects of MgCl₂ on specificity and comparison with binding of Myc family members. Nucleic Acids Res. 22:2801–2810. 1994. View Article : Google Scholar : PubMed/NCBI
23	Krag S, Danielsen CC, Carmeliet P, Nyengaard J and Wogensen L: Plasminogen activator inhibitor-1 gene deficiency attenuates TGF-beta1-induced kidney disease. Kidney Int. 68:2651–2666. 2005. View Article : Google Scholar : PubMed/NCBI
24	Wang AY, Poon P, Lai FM, Yu L, Choi PC and Lui SF: Plasminogen activator inhibitor-1 gene polymorphism 4G/4G genotype and lupus nephritis in Chinese patients. Kidney Int. 59:1520–1528. 2001. View Article : Google Scholar : PubMed/NCBI
25	Suzuki H, Sakuma Y, Kanesaki Y, Eiro M, Asahi K, Sanada H, Watanabe K, Katoh T and Watanabe T: Close relationship of plasminogen activator inhibitor-1 4G/5G polymorphism and progression of IgA nephropathy. Clin Nephrol. 62:173–179. 2004. View Article : Google Scholar : PubMed/NCBI
26	He D, Li J, Zhao J, Fei J and Zhang X: C/EBP homologous protein induces mesangial cell apoptosis under hyperglycemia. Mol Med Rep. 7:445–448. 2013.PubMed/NCBI
27	Izuhara Y, Yamaoka N, Kodama H, Dan T, Takizawa S, Hirayama N, Meguro K, van Ypersele de Strihou C and Miyata T: A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates. J Cerebr Blood F Met. 30:904–912. 2010. View Article : Google Scholar : PubMed/NCBI
28	Dieval J, Nguyen G, Gross S, Delobel J and Kruithof EK: A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1. Blood. 77:528–532. 1991.PubMed/NCBI
29	Fay WP, Parker AC, Condrey LR and Shapiro AD: Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. Blood. 90:204–208. 1997.PubMed/NCBI
30	Fay WP, Shapiro AD, Shih JL, Schleef RR and Ginsburg D: Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Eng J Med. 327:1729–1733. 1992. View Article : Google Scholar : PubMed/NCBI